Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly. Pfizer ...
Allure on MSN
A skin cancer vaccine may be on the horizon
The personalized mRNA-based vaccine could help prevent recurrent melanoma.
A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer ...
Ordinarily, surgery for brain tumors is followed by up to six weeks of recovery before radiation treatments begin. In the ...
Nearly a decade later, taking the center stage at ASCO 2026, Akeso’s ivonescimab made history by offering the first-ever ...
Today we revisit the American Society of Clinical Oncology scientific meeting in Chicago, which concluded on Tuesday, to report on three more potentially practice-changing studies.
A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer ...
On May 12, 2026, the Patent Trial and Appeal Board (“PTAB”) issued a Final Written Decision (“FWD”) in PGR2025-00003 finding all challenged claims of Halozyme’s U.S. Patent No. 11,952,600 (“the ’600 ...
Revolution Medicines stole the show at the 2026 American Society of Clinical Oncology meeting as full data from its pancreatic cancer drug lived up to expectations, while Summit and Akeso proved the ...
Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration.
About $300 billion in revenue generated by rated pharmaceutical companies is expected to face generic and biosimilar competition through 2031 — a shift with direct implications for how hospitals and ...
More biopharma layoffs are hitting New Jersey, this time from Merck & Co.in the latest phase of headcount reductions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results